AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Astrazeneca Plc ended up being:
Its compound free cash flow growth rate, as measured over the past 5.75 years, is -0.09% -- higher than only 14.77% of stocks in our DCF forecasting set.
As a business, AZN is generating more cash flow than 89.13% of positive cash flow stocks in the Healthcare.
Astrazeneca Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 16.49% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
GMED, NRC, BAX, CNC, and MTD can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The FDA has granted Breakthrough Therapy Designation to AstraZeneca’s (AZN) Farxiga for the treatment of patients with chronic kidney disease, with and without type-2 diabetes.Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the...
Following a review of safety data by an independent committee, a Phase 1/2 clinical trial evaluating AstraZeneca's (AZN) COVID-19 vaccine candidate, AZD1222, has resumed in Japan following earlier restarts in the U.K., Brazil, South Africa and India.The U.S. study has yet to resume....
Trials on the coronavirus vaccine developed by AstraZeneca and Oxford University have resumed in Japan but not the United States, where the pharmaceutical giant is working with regulators, a statement released said.